Pharmaceutical

MSD closes $1.3bn EyeBio acquisition, plans pivotal trial for lead asset

MSD (Merck & Co) plans to start a Phase IIb/III trial for EyeBio’s lead candidate, Restoret, in diabetic macular oedema in H2.

Jul 14, 2024 - 04:00
MSD closes $1.3bn EyeBio acquisition, plans pivotal trial for lead asset
MSD (Merck & Co) plans to start a Phase IIb/III trial for EyeBio’s lead candidate, Restoret, in diabetic macular oedema in H2.
Read the original article

Tags:

Previous Article

Crossject secures funding from French Government for needle-free platform

Next Article

Explainer: Labour has been elected in the UK – now what?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: OB-GYNs could have solidified abortion as health care after Roe. They missed their chance

Opinion: OB-GYNs could have solidified abortion as heal...

Jun 24, 2023

FDA withdraws approval of preterm birth drug Makena

FDA withdraws approval of preterm birth drug Makena

Apr 8, 2023

BridgeBio secures $1.25bn for genetic therapy development

BridgeBio secures $1.25bn for genetic therapy development

Jan 19, 2024